MB BCh, PhD, FRCP
Professor of Metabolic Endocrinology
My work tries to better understand and treat metabolic diseases, in particular, non-alcholic fatty liver disease (NAFLD). Our work has focused on the role of steroid hormones and their metabolism in the development, assessment and treatment of metabolic diseases including NAFLD, obesity and type 2 diabetes. Our previous work has shown that altering steroid hormone metabolism can have a potent impact on the function of both liver and adipose tissue to store fat. Our future work will use steroid biomarkers not only to stage disease severity, but to predict progression. In addition, by altering tissue specific-metabolism, we hope to limit the side effects of prescribed steroids.
Is autonomous cortisol secretion sexually dimorphic?
Pofi R. and Tomlinson JW., (2022), Lancet Diabetes Endocrinol
AKR1D1 knockout mice develop a sex-dependent metabolic phenotype.
Gathercole LL. et al, (2022), J Endocrinol, 253, 97 - 113
Is it time for chronopharmacology in NASH?
Marjot T. et al, (2022), J Hepatol
Sex hormones, adiposity, and metabolic traits in men and women: a Mendelian Randomisation study.
CHRISTODOULIDES C., (2022), European Journal of Endocrinology
Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis.
Green CJ. et al, (2022), Eur J Endocrinol